Last reviewed · How we verify
Human interferon α1b Inhalation Solution
Human interferon α1b activates innate immune responses by binding to interferon-alpha receptors on immune and epithelial cells, enhancing antiviral and immunomodulatory activity.
Human interferon α1b activates innate immune responses by binding to interferon-alpha receptors on immune and epithelial cells, enhancing antiviral and immunomodulatory activity. Used for Viral respiratory infections (Phase 3 development), COVID-19 (potential indication under investigation).
At a glance
| Generic name | Human interferon α1b Inhalation Solution |
|---|---|
| Sponsor | Kexing Biopharm Co., Ltd. |
| Drug class | Interferon alpha |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Interferon α1b is a recombinant human interferon that engages type I interferon receptors (IFNAR1/IFNAR2) on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral genes, enhance natural killer cell activity, and promote Th1-mediated immune responses. When delivered via inhalation, it provides local immune activation in the respiratory tract, making it particularly suited for viral respiratory infections.
Approved indications
- Viral respiratory infections (Phase 3 development)
- COVID-19 (potential indication under investigation)
Common side effects
- Fever
- Fatigue
- Headache
- Myalgia
- Local respiratory irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: